Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Turesson

Showing results (101-110 of 113) with videos related to

Pageof 12
Sort By:
Blood Cancer Journal|March 25, 2014
Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglinO E Olsen, K F Wader, K Misund, et al.
Medical Oncology (Northwood, London, England)|January 10, 2002
Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell supportN Gulbrandsen, F Wisløff, L Brinch, et al.
Blood|December 23, 1999
Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study GroupS Lenhoff, M Hjorth, E Holmberg, et al.
Leukemia|September 13, 2003
No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative diseaseR Hast, E Hellström-Lindberg, L Ohm, et al.
Leukemia|April 23, 2010
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and managementR A Kyle, B G M Durie, S V Rajkumar, et al.
Leukemia|July 21, 2006
International uniform response criteria for multiple myelomaB G M Durie, J-L Harousseau, J S Miguel, et al.
Leukemia|November 21, 2008
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disordersA Dispenzieri, R Kyle, G Merlini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2016
Second primary malignancies in multiple myeloma: an overview and IMWG consensusP Musto, K C Anderson, M Attal, et al.
Leukemia|June 5, 2009
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantationA Palumbo, O Sezer, R Kyle, et al.
Leukemia|November 21, 2013
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)E M Ocio, P G Richardson, S V Rajkumar, et al.
Pageof 12

Showing results (101-110 of 113) with videos related to

Sort By:
Pageof 12
Blood Cancer Journal|March 25, 2014
Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglinO E Olsen, K F Wader, K Misund, et al.
Medical Oncology (Northwood, London, England)|January 10, 2002
Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell supportN Gulbrandsen, F Wisløff, L Brinch, et al.
Blood|December 23, 1999
Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study GroupS Lenhoff, M Hjorth, E Holmberg, et al.
Leukemia|September 13, 2003
No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative diseaseR Hast, E Hellström-Lindberg, L Ohm, et al.
Leukemia|April 23, 2010
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and managementR A Kyle, B G M Durie, S V Rajkumar, et al.
Leukemia|July 21, 2006
International uniform response criteria for multiple myelomaB G M Durie, J-L Harousseau, J S Miguel, et al.
Leukemia|November 21, 2008
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disordersA Dispenzieri, R Kyle, G Merlini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2016
Second primary malignancies in multiple myeloma: an overview and IMWG consensusP Musto, K C Anderson, M Attal, et al.
Leukemia|June 5, 2009
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantationA Palumbo, O Sezer, R Kyle, et al.
Leukemia|November 21, 2013
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)E M Ocio, P G Richardson, S V Rajkumar, et al.
Pageof 12